Skip to Main Content
Menu Button
About Us
The ModeX Mission
Leadership
Our Journey
OPKO Health
Science
Our Approach
Our MSTAR Platform
Our Nanoparticle Vaccine Platform
Publications, Posters, and Presentations
Pipeline
People
Careers
Life at ModeX
News & Events
Press Releases
OPKO News Feed
October 29, 2025
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
Read More
October 28, 2025
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
Read More
June 9, 2025
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
Read More
January 9, 2025
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck
Read More
View More
March 20, 2023
2023 R&D Day
Read More
July 15, 2025
A PHASE 1/2A, MULTICENTER, FIRST-IN-HUMAN, OPEN-LABEL CLINICAL TRIAL EVALUATING MDX2001, A TETRASPECIFIC T CELL ENGAGER-EXPANDER IN PATIENTS WITH ADVANCED SOLID TUMOR (NCT06239194)
Read More
Follow us on
LINKEDIN
and
TWITTER
for the latest news.
Have a Question?
Email
media@modextx.com
Learn more about our vision and the team behind it
ABOUT US
